09/13 $REGN New SEC Document(s) for Regeneron Pharmaceuticals, Inc. From our Stock .. 09/13 Overbrook Management Corp Invests $618,000 in Regeneron Pharmaceuticals, Inc... 09/13 Sanofi $SNY Stake Decreased by …
Paris, France and Tarrytown, New York - September 8, 2017 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to …
In afternoon trading on the stock market today, Regeneron sank 5.6%, near 472, …
And for a while, that worked: Shares of Regeneron gained 23% from early May through its June peak. But it's given back more than half those gains now, …
Among the S&P 500’s biggest fallers on Thursday September 07 was Regeneron Pharmaceuticals Inc. (REGN). The stock experienced a 5.66% decline to $471.92 with 1.55 million shares changing hands. Regeneron Pharmaceuticals …
Regeneron Pharmaceuticals Inc. REGN, -0.09% shares surged 6.6% in midday trade Tuesday after Novartis AG NVS, +0.39% released positive data for two late-stage trials comparing its eye disease drug head-to-head with Regeneron's …
In fact, REGN has been the worst S&P 500 Index (SPX) stock to own in the month of June, averaging the steepest loss of 10.14%. Regeneron stock could be due for a breather, too. The shares have surged 31% in 2017, and sport a 14-day …
After posting better-than-expected first-quarter results, Regeneron Pharmaceuticals (NASDAQ: REGN) stock enjoyed a nice bounce. The biotech announced solid sales for eye-disease drug Eylea and a strong launch for atopic dermatitis …
Regeneron Pharmaceuticals Inc. shares surged 6.6% in midday trade Tuesday after Novartis AG released positive data for two late-stage trials comparing its eye disease drug head-to-head with Regeneron's Eylea. The drug, RTH258, met …